Alnylam Pharmaceuticals Inc

ALNY

NASDAQ. Currency in USD

200.16 -9.23 ( -4.41% )

Real time prices: September 30

Market Cap.
24.02B
Beta (5Y monthly)
0.57
Price/Earnings
-
EPS (TTM)
-8.17
Forward Dividend
0.00 (0.00%)
Ex-Dividend Date
Volume
1.68M
1y Target Est.
238.73
Day's Range
199.11
-
216.89
52 Week's Range
117.58
-
236.80

Historical Summary

Performance
EPS growth
Share Buybacks

About Alnylam Pharmaceuticals Inc

Sector
Healthcare
Industry
Biotechnology
Website
https://www.alnylam.com
Exchange
NASDAQ (XNAS)
Shares Outstanding
119.60M
Employees
1665
Address
675 West Kendall Street, Cambridge, MA, United States, 02142
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Latest news

Biotech Stock Roundup: GILD, BMY's Regulatory News, BLUE's Therapy Approval & More
Biotech Stock Roundup: GILD, BMY's Regulatory News, BLUE's Therapy Approval & More

Regulatory and pipeline updates from BMY and GILD are the key highlights from the biotech...
By Zacks Investment Research - 1 week ago

Alnylam's (ALNY) Rare Disease Drug Amvuttra Gets EC Nod
Alnylam's (ALNY) Rare Disease Drug Amvuttra Gets EC Nod

The European Commission approves Alnylam's (ALNY) Amvuttra for treating hereditary transthyretin-mediated (hATTR) amyloidosis in adult...
By Zacks Investment Research - 1 week ago

Analysts Put Alnylam On Upside Catalyst Watch Ahead Of Upcoming Data From Lead Program
Analysts Put Alnylam On Upside Catalyst Watch Ahead Of Upcoming Data From Lead Program

RBC Capital Markets raised the price target on Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) from $225...
By Benzinga - 1 week ago

Regeneron (REGN)/ Alnylam Report Promising Data from NASH Study
Regeneron (REGN)/ Alnylam Report Promising Data from NASH Study

Regeneron (REGN) and its partner Alnylam announce promising data from its ongoing phase I study...
By Zacks Investment Research - 2 weeks ago

Where Alnylam Pharmaceuticals Stands With Analysts
Where Alnylam Pharmaceuticals Stands With Analysts

Within the last quarter, Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings: Bullish Somewhat...
By Benzinga - 3 weeks ago

Analyst Ratings for Alnylam Pharmaceuticals
Analyst Ratings for Alnylam Pharmaceuticals

Analysts have provided the following ratings for Alnylam Pharmaceuticals (NASDAQ:ALNY) within the last quarter: Bullish...
By Benzinga - 3 weeks ago

Alnylam (ALNY) Soars 8.4%: Is Further Upside Left in the Stock?
Alnylam (ALNY) Soars 8.4%: Is Further Upside Left in the Stock?

Alnylam (ALNY) witnessed a jump in share price last session on above-average trading volume. The...
By Zacks Investment Research - 3 weeks ago

Want to Beat Alphabet Stock? Buy These 2 Winners of the Bear Market
Want to Beat Alphabet Stock? Buy These 2 Winners of the Bear Market

They're both soaring thanks to a handful of recent catalysts.
By The Motley Fool - 4 weeks ago